Table 3 Molecular subtypes in association with breast cancer survival, the Shanghai Breast Cancer Survival Study.
| Â | Overall survival | Disease-free survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Cases | Events | 5-yr survival rate | HR1* (95% CI) | HR2** (95% CI) | Cases | Events | 5-yr survival rate | HR1* (95% CI) | HR2** (95% CI) |
Luminal A | 1258 | 97 | 0.9286 | 1.00 | 1.00 | 1234 | 121 | 0.8863 | 1.00 | 1.00 |
Luminal B | 419 | 48 | 0.8862 | 1.57 (1.10 - 2.22) | 1.17 (0.82 - 1.68) | 410 | 57 | 0.8506 | 1.42 (1.03 - 1.95) | 1.04 (0.75 - 1.43) |
HER2 | 322 | 60 | 0.8322 | 2.12 (1.50 - 3.00) | 1.47 (1.03 - 2.10) | 312 | 70 | 0.7907 | 1.94 (1.41 - 2.67) | 1.32 (0.95 - 1.83) |
Triple-negative | 298 | 62 | 0.8069 | 2.50 (1.78 - 3.51) | 1.87 (1.31 - 2.66) | 292 | 68 | 0.7600 | 2.12 (1.55 - 2.91) | 1.52 (1.09 - 2.11) |
HER2 borderline | 204 | 23 | 0.8768 | 1.46 (0.93 - 2.32) | 1.42 (0.90 - 2.26) | 202 | 25 | 0.8788 | 1.19 (0.77 - 1.84) | 1.15 (0.75 - 1.79) |